Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice

Neuropsychopharmacology volume 48, pages 1257–1266 (2023)Cite this article

Subjects

Abstract

Serotonergic psychedelics are gaining increasing interest as potential therapeutics for a range of mental illnesses. Compounds with short-lived subjective effects may be clinically useful because dosing time would be reduced, which may improve patient access. One short-acting psychedelic is 5-MeO-DMT, which has been associated with improvement in depression and anxiety symptoms in early phase clinical studies. However, relatively little is known about the behavioral and neural mechanisms of 5-MeO-DMT, particularly the durability of its long-term effects. Here we characterized the effects of 5-MeO-DMT on innate behaviors and dendritic architecture in mice. We showed that 5-MeO-DMT induces a dose-dependent increase in head-twitch response that is shorter in duration than that induced by psilocybin at all doses tested. 5-MeO-DMT also substantially suppresses social ultrasonic vocalizations produced during mating behavior. 5-MeO-DMT produces long-lasting increases in dendritic spine density in the mouse medial frontal cortex that are driven by an elevated rate of spine formation. However, unlike psilocybin, 5-MeO-DMT did not affect the size of dendritic spines. These data provide insights into the behavioral and neural consequences underlying the action of 5-MeO-DMT and highlight similarities and differences with those of psilocybin.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: 5-MeO-DMT elicits a briefer duration of head-twitch response than psilocybin.
Fig. 2: Classical psychedelics and ketamine suppress the production of social ultrasonic vocalizations.
Fig. 3: 5-MeO-DMT increases the density of dendritic spines, but does not affect spine size, in the mouse medial frontal cortex.
Fig. 4: 5-MeO-DMT increases the formation rate of dendritic spines.

Data availability

The data that support the findings and the code used to analyze the data in this study are available at https://github.com/Kwan-Lab.

Code availability

The data that support the findings and the code used to analyze the data in this study are available at https://github.com/Kwan-Lab.

References

  1. Vollenweider FX, Preller KH. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611–24.

    CAS  PubMed  Google Scholar 

  2. Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry’s brave new World. Cell 2020;181:24–8.

    CAS  PubMed  Google Scholar 

  3. Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics 2017;14:734–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. Curr Biol. 2022;32:R63–R67.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022;25:1407–19.

  6. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402–11.

    CAS  PubMed  Google Scholar 

  7. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2021;78:481–9.

    PubMed  Google Scholar 

  8. Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry. 2016;3:619–27.

    PubMed  Google Scholar 

  9. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacol (Berl). 2004;172:145–56.

    CAS  Google Scholar 

  10. Reckweg J, Mason NL, van Leeuwen C, Toennes SW, Terwey TH, Ramaekers JG. A Phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. Front Pharm. 2021;12:760671.

    Google Scholar 

  11. Shulgin A, Shulgin A. TiHKAL: The Continuation. Transform Press: Berkeley, CA; 2002.

  12. Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E. The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol. 2018;32:779–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Barsuglia J, Davis AK, Palmer R, Lancelotta R, Windham-Herman AM, Peterson K, et al. Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. Front Psychol. 2018;9:2459.

    PubMed  PubMed Central  Google Scholar 

  14. Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abus. 2019;45:161–9.

    Google Scholar 

  15. Uthaug MV, Lancelotta R, van Oorsouw K, Kuypers KPC, Mason N, Rak J, et al. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacol (Berl). 2019;236:2653–66.

    CAS  Google Scholar 

  16. Ermakova AO, Dunbar F, Rucker J, Johnson MW. A narrative synthesis of research with 5-MeO-DMT. J Psychopharmacol. 2021. 2698811211050543.

  17. Reckweg JT, Uthaug MV, Szabo A, Davis AK, Lancelotta R, Mason NL, et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J Neurochem. 2022;162:128–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA. The paradox of 5-methoxy-N,N-dimethyltryptamine: An indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav. 2000;65:75–82.

    CAS  PubMed  Google Scholar 

  19. Shen HW, Jiang XL, Winter JC, Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010;11:659–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Ray TS. Psychedelics and the human receptorome. PLoS One. 2010;5:e9019.

    PubMed  PubMed Central  Google Scholar 

  21. Savalia NK, Shao LX, Kwan AC. A dendrite-focused framework for understanding the actions of ketamine and psychedelics. Trends Neurosci. 2021;44:260–75.

    CAS  PubMed  Google Scholar 

  22. Carhart-Harris RL, Nutt DJ. Serotonin and brain function: A tale of two receptors. J Psychopharmacol. 2017;31:1091–120.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Halberstadt AL, Koedood L, Powell SB, Geyer MA. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol. 2011;25:1548–61.

    CAS  PubMed  Google Scholar 

  24. Dunlap LE, Azinfar A, Ly C, Cameron LP, Viswanathan J, Tombari RJ, et al. Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies. J Med Chem. 2020;63:1142–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, et al. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci. 2023;14:351–58.

    CAS  PubMed  Google Scholar 

  26. de Montigny C, Aghajanian GK. Preferential Action of 5-Methoxytryptamine and 5-Methoxydimethyltryptamine on Presynaptic Serotonin Receptors - Comparative Iontophoretic Study with Lsd and Serotonin. Neuropharmacology 1977;16:811–8.

    Google Scholar 

  27. Trulson ME, Jacobs BL. Effects of 5-methoxy-N,N-dimethyltryptamine on behavior and raphe unit activity in freely moving cats. Eur J Pharm. 1979;54:43–50.

    CAS  Google Scholar 

  28. Winne J, Boerner BC, Malfatti T, Brisa E, Doerl J, Nogueira I, et al. Anxiety-like behavior induced by salicylate depends on age and can be prevented by a single dose of 5-MeO-DMT. Exp Neurol. 2020;326:113175.

    CAS  PubMed  Google Scholar 

  29. Lima da Cruz RV, Moulin TC, Petiz LL, Leao RN. A Single Dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus. Front Mol Neurosci. 2018;11:312.

    PubMed  PubMed Central  Google Scholar 

  30. Dakic V, Minardi Nascimento J, Costa Sartore R, Maciel RM, de Araujo DB, Ribeiro S, et al. Short-term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Sci Rep. 2017;7:12863.

    PubMed  PubMed Central  Google Scholar 

  31. Riga MS, Soria G, Tudela R, Artigas F, Celada P. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs. Int J Neuropsychopharmacol. 2014;17:1269–82.

    CAS  PubMed  Google Scholar 

  32. Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1529.

    PubMed  PubMed Central  Google Scholar 

  33. Liston C, Miller MM, Goldwater DS, Radley JJ, Rocher AB, Hof PR, et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci. 2006;26:7870–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Radley JJ, Rocher AB, Miller M, Janssen WG, Liston C, Hof PR, et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex. 2006;16:313–20.

    PubMed  Google Scholar 

  35. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Phoumthipphavong V, Barthas F, Hassett S, Kwan AC. Longitudinal effects of ketamine on dendritic architecture in vivo in the mouse medial frontal cortex. eNeuro 2016;3:ENEURO.0133–15.2016.

    PubMed  PubMed Central  Google Scholar 

  37. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69:754–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat8078.

  39. Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 2021;109:2535–44.e4.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci USA. 2009;106:19575–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci USA. 2021;118:e2022489118.

  43. Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, et al. A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int J Mol Sci. 2021;22:835.

  44. de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37:109836.

    PubMed  Google Scholar 

  45. Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021;589:474–79.

    CAS  PubMed  Google Scholar 

  46. Sherwood AM, Claveau R, Lancelotta R, Kaylo KW, Lenoch K. Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use. ACS Omega. 2020;5:32067–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Halberstadt AL, Geyer MA. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacol (Berl). 2013;227:727–39.

    CAS  Google Scholar 

  48. de la Fuente Revenga M, Vohra HZ, Gonzalez-Maeso J. Automated quantification of head-twitch response in mice via ear tag reporter coupled with biphasic detection. J Neurosci Methods. 2020;334:108595.

    PubMed  PubMed Central  Google Scholar 

  49. Castellucci GA, Calbick D, McCormick D. The temporal organization of mouse ultrasonic vocalizations. PLoS One. 2018;13:e0199929.

    PubMed  PubMed Central  Google Scholar 

  50. Fonseca AH, Santana GM, Bosque Ortiz GM, Bampi S, Dietrich MO. Analysis of ultrasonic vocalizations from mice using computer vision and machine learning. Elife. 2021;10:e59161.

  51. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Thevenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process. 1998;7:27–41.

    CAS  PubMed  Google Scholar 

  53. McKinney W. Data structures for statistical computing in Python. Proc. of the 9th Python in Science Conf. 2010;445:51–6.

  54. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 1.0: Fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17:261–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Waskom M. seaborn: statistical data visualization. Journal of Open Source Software. 2021;6:3021.

  56. Corne SJ, Pickering RW. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia (Berl). 1967;11:65–78.

    CAS  Google Scholar 

  57. Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology 2020;167:107933.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Schmitz GP, Jain MK, Slocum ST, Roth BL. 5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics. ACS Chem Neurosci. 2022;13:2386–98.

    CAS  PubMed  Google Scholar 

  59. Holy TE, Guo Z. Ultrasonic songs of male mice. PLoS Biol. 2005;3:e386.

    PubMed  PubMed Central  Google Scholar 

  60. Neunuebel JP, Taylor AL, Arthur BJ, Egnor SE. Female mice ultrasonically interact with males during courtship displays. Elife. 2015;4:e06203.

  61. Davoudian PA, Shao LX, Kwan AC. Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. ACS Chem Neurosci. 2023;14:468–80.

    CAS  PubMed  Google Scholar 

  62. Ali F, Gerhard DM, Sweasy K, Pothula S, Pittenger C, Duman RS, et al. Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. Nat Commun. 2020;11:72.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000;28:41–51.

    CAS  PubMed  Google Scholar 

  64. Holtmaat A, Bonhoeffer T, Chow DK, Chuckowree J, De Paola V, Hofer SB, et al. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protoc. 2009;4:1128–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Yanni PA, Lindsley TA. Ethanol inhibits development of dendrites and synapses in rat hippocampal pyramidal neuron cultures. Brain Res Dev Brain Res. 2000;120:233–43.

    CAS  PubMed  Google Scholar 

  66. Munoz-Cuevas FJ, Athilingam J, Piscopo D, Wilbrecht L. Cocaine-induced structural plasticity in frontal cortex correlates with conditioned place preference. Nat Neurosci. 2013;16:1367–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N, Nakahara H. Structure–stability–function relationships of dendritic spines. Trends Neurosci. 2003;26:360–8.

    CAS  PubMed  Google Scholar 

  68. Holler S, Kostinger G, Martin KAC, Schuhknecht GFP, Stratford KJ. Structure and function of a neocortical synapse. Nature 2021;591:111–16.

    CAS  PubMed  Google Scholar 

  69. Jurgens U. Neural pathways underlying vocal control. Neurosci Biobehav Rev. 2002;26:235–58.

    PubMed  Google Scholar 

  70. Tschida K, Michael V, Takatoh J, Han BX, Zhao S, Sakurai K, et al. A Specialized Neural Circuit Gates Social Vocalizations in the Mouse. Neuron 2019;103:459–72.e4.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Lefler Y, Campagner D, Branco T. The role of the periaqueductal gray in escape behavior. Curr Opin Neurobiol. 2020;60:115–21.

    CAS  PubMed  Google Scholar 

  72. Fish EW, Sekinda M, Ferrari PF, Dirks A, Miczek KA. Distress vocalizations in maternally separated mouse pups: modulation via 5-HT(1A), 5-HT(1B) and GABA(A) receptors. Psychopharmacol (Berl). 2000;149:277–85.

    CAS  Google Scholar 

  73. Takahashi A, Yap JJ, Bohager DZ, Faccidomo S, Clayton T, Cook JM, et al. Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacol (Berl). 2009;204:61–71.

    CAS  Google Scholar 

  74. Budylin T, Guariglia SR, Duran LI, Behring BM, Shaikh Z, Neuwirth LS, et al. Ultrasonic vocalization sex differences in 5-HT(1A)-R deficient mouse pups: Predictive phenotypes associated with later-life anxiety-like behaviors. Behav Brain Res. 2019;373:112062.

    CAS  PubMed  Google Scholar 

  75. Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 2022;375:403–11.

    CAS  PubMed  Google Scholar 

  76. Kaplan AL, Confair DN, Kim K, Barros-Alvarez X, Rodriguiz RM, Yang Y, et al. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature. 2022;610:582–91.

Download references

Acknowledgements

We thank Ling-Xiao Shao for advice on imaging, Neil Savalia for advice on statistical analyses, Gregg Castellucci and Katherine Tschida for advice on measuring ultrasonic vocalizations, Antonio Fonseca for advice on the VocalMat software, and Janghoo Lim for loaning equipment for recording ultrasonic vocalizations. 5-MeO-DMT-succinate was generously provided by Usona Institute’s Investigational Drug & Material Supply Program; the Usona Institute IDMSP is supported by Alexander Sherwood, Robert Kargbo, and Kristi Kaylo in Madison, WI. The behavioral experiments were supported by the Yale Program in Psychedelic Science, NIH/NIMH grant R01MH121848 (A.C.K.), NIH/NIMH grant R01MH128217 (A.C.K.), One Mind – COMPASS Rising Star Award (A.C.K.), and NIH/NIGMS medical scientist training grant T32GM007205 (P.A.D.). The imaging experiments were supported by a sponsored research project from Freedom Biosciences (C.P., S.J.J.), NIH/NINDS training grant T32NS041228 (C.L.), China Scholarship Council-Yale World Scholars Fellowship (H.W.), and NIH/NIMH training grant T32MH019961 (S.J.J.).

Author information

Authors and Affiliations

  1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, 06511, USA

    Sarah J. Jefferson, Ian Gregg, Mark Dibbs, Patrick H. Wehrle, Alfred P. Kaye, Christopher Pittenger & Alex C. Kwan

  2. Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, CT, 06511, USA

    Clara Liao, Hao Wu & Pasha A. Davoudian

  3. Medical Scientist Training Program, Yale University School of Medicine, New Haven, CT, 06511, USA

    Pasha A. Davoudian

  4. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, 14853, USA

    Samuel C. Woodburn & Alex C. Kwan

  5. Freedom Biosciences, Tiburon, CA, 94920, USA

    Jeffrey S. Sprouse

  6. Usona Institute, Madison, WI, 53711, USA

    Alexander M. Sherwood

  7. VA National Center for PTSD Clinical Neuroscience Division, West Haven, CT, 06516, USA

    Alfred P. Kaye

  8. Child Study Center, Yale University School of Medicine, New Haven, CT, 06511, USA

    Christopher Pittenger

  9. Department of Neuroscience, Yale University School of Medicine, New Haven, CT, 06511, USA

    Alex C. Kwan

  10. Department of Psychiatry, Weill Cornell Medicine, New York, NY, 10065, USA

    Alex C. Kwan

Authors
  1. Sarah J. Jefferson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian Gregg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Dibbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Clara Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pasha A. Davoudian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Samuel C. Woodburn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patrick H. Wehrle
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jeffrey S. Sprouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Alexander M. Sherwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Alfred P. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Christopher Pittenger
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Alex C. Kwan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SJJ, CP, and ACK designed the research. SJJ performed the two-photon imaging experiments and analyzed the data. IG performed the ultrasonic vocalization experiments and analyzed the data. MD performed the head-twitch response experiments and analyzed the data. CL and HW assisted in the two-photon imaging experiments. PAD worked with MD to make the equipment for using magnetic ear tags to measure head-twitch response and analyzed the data. SCW and PW contributed to behavioral experiments. JSS contributed to the experimental design. AMS synthesized and provided the 5-MeO-DMT succinate. CP and APK contributed to data interpretation. SJJ and ACK wrote the paper with input from other authors.

Corresponding author

Correspondence to Alex C. Kwan.

Ethics declarations

Competing interests

ACK is a member of the Scientific Advisory Board of Empyrean Neuroscience and Freedom Biosciences. ACK has consulted for Biohaven Pharmaceuticals. No-cost compounds were provided to ACK for research by Usona Institute. CP has served as a consultant in the past year for Biohaven Pharmaceuticals, Teva Pharmaceuticals, and Brainsway Therapeutics and has performed research under contract with Biohaven and with Blackthorn Therapeutics, Ltd., on unrelated projects. CP and APK have performed research under contract with Transcend Therapeutics on unrelated projects. CP and SJJ have a sponsored research agreement with Freedom Biosciences. The sponsor of this research was not involved in the analyses or writing of the manuscript. The duties had no influence on the content of this article. The remaining authors have nothing to disclose.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jefferson, S.J., Gregg, I., Dibbs, M. et al. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacol. 48, 1257–1266 (2023). https://doi.org/10.1038/s41386-023-01572-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41386-023-01572-w

This article is cited by

Search

Advanced search

Quick links